(±)-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane
- 3 June 2005
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 314 (3), 1002-1012
- https://doi.org/10.1124/jpet.105.088476
Abstract
We showed that the serotonin (5-HT) neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) reduces brain tissue 5-HT, decreases expression of 5-HT transporter (SERT) protein, and increases expression of glial fibrillary acidic protein (GFAP). In contrast, doses of (±)-3,4-methylenedioxymethamphetamine (MDMA) that decrease brain tissue 5-HT fail to alter expression of SERT or GFAP. Using a new and highly sensitive anti-SERT antibody, we determined whether MDMA alters the subcellular distribution of SERT protein by measuring SERT expression in endosomes and plasma membranes 2 weeks after MDMA administration. Rat brain tissues (caudate, cortex, and hippocampus) were collected 3 days and 2 weeks after MDMA (7.5 mg/kg i.p., every 2 h × 3 doses) or 5,7-DHT (150 μg/rat i.c.v.) administration. Representative results from cortex are as follows. At both 3 days and 2 weeks postinjection, MDMA decreased tissue 5-HT (65%) and had no effect on GFAP expression. MDMA increased heat shock protein 32 (HSP32; a marker for microglial activation) expression (30%) at 3 days, but not 2 weeks. MDMA did not alter SERT expression at either time point and did not alter SERT levels in either endosomes or plasma membranes (2 weeks). 5,7-DHT decreased tissue 5-HT (80%), increased HSP32 expression at both time points (about 50%), and increased GFAP expression at 2 weeks (40%). 5,7-DHT decreased SERT expression (33%) at 2 weeks, but not at 3 days. These findings indicate that a dosing regimen of MDMA that depletes brain 5-HT does not alter SERT protein expression or the distribution of SERT between endosomes and the plasma membrane and does not produce detectable evidence for neurotoxicity.Keywords
This publication has 40 references indexed in Scilit:
- Differential Effects of Amphetamines-Induced Neurotoxicity on Appetitive and Aversive Pavlovian Conditioning in MiceNeuropsychopharmacology, 2005
- Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humansTrends in Pharmacological Sciences, 2004
- Drug Abuse Trends among Youth in the United StatesAnnals of the New York Academy of Sciences, 2004
- Peripheral benzodiazepine receptors and mitochondrial functionNeurochemistry International, 2002
- Serotonergic Neurotoxicity of 3,4-(±)-Methylenedioxyamphetamine and 3,4-(±)-Methylendioxymethamphetamine (Ecstasy) Is Potentiated by Inhibition of γ-Glutamyl TranspeptidaseChemical Research in Toxicology, 2001
- α-Lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicityNeuroReport, 1999
- Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in RatsJournal of Neuroscience, 1998
- Effects of (+)-fenfluramine on 3,4-methylenedioxymethamphetamine (MDMA) discrimination in ratsPharmacology Biochemistry and Behavior, 1996
- Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat?Brain Research Bulletin, 1994
- Investigation of MDMA-related agents in rats trained to discriminate MDMA from salinePharmacology Biochemistry and Behavior, 1992